SMC Laboratories has conducted nonclinical pharmacology study services for over 10 years and has over 500 clients worldwide. It was our proprietary STAM™ mice model that made us a leading CRO in NASH-HCC research field. Our expertise in fibrotic and inflammatory diseases make us a fit choice for clients to get the most out of their studies.
Our STAM™ model is a model that recapitulates the same disease progression as human NASH/HCC. In this model, male C57BL/6 mice aged two days are given a single dose of streptozotocin to reduce insulin secretory capacity. When the mice turn four weeks of age they start a high-fat diet feeding. This model has a background of late type 2 diabetes which progresses into fatty liver, NASH, fibrosis and consequently liver cancer (HCC). Compared to other NASH-HCC model mice, the disease progresses in a relatively short period of time, and liver cancer is developed in 100% of animals at 20 weeks of age. Thus, our model is widely used in NASH research, with more than 40 papers (seen left of the figure shown below) and 70 international conferences (listed right of the figure shown below) published using data from our STAM™ model so far.
SMC Laboratories, Inc. has not received any reviews.
SMC Laboratories, Inc. has not received any endorsements.